TY - JOUR
T1 - Chronic prurigo in an adolescent patient successfully controlled with dupilumab
AU - Al-Abdulla, Mohammed Nasser
AU - Al-Qahtani, Noof
AU - Younis, Shahd M.
AU - Rizvi, Syed
AU - Elfaieg, Amro
AU - Buddenkotte, Joerg
AU - Steinhoff, Martin
N1 - Publisher Copyright:
© The Author(s) 2026. Published by Oxford University Press on behalf of British Association of Dermatologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
PY - 2026/8
Y1 - 2026/8
N2 - Chronic prurigo, formerly termed prurigo nodularis, is a chronic skin condition characterized by intensely itchy nodules and papules. It primarily affects adults, particularly middle-aged women. The aetiology of chronic prurigo is unclear, but it can be associated with primary skin dermatoses and systemic conditions. Minimal data on chronic prurigo in children are available in the literature. While systemic therapies for chronic prurigo have significant side effects, targeted biologic and small-molecule inhibitors offer a promising treatment option with a good benefit–risk ratio. We report one of the first cases of an adolescent with chronic prurigo that was successfully controlled with dupilumab. Dupilumab treatment resulted in a fast, significant and sustainable improvement in the signs and symptoms of chronic prurigo, with favourable safety and tolerability profiles, highlighting its potential for recalcitrant cases and long-term remission.
AB - Chronic prurigo, formerly termed prurigo nodularis, is a chronic skin condition characterized by intensely itchy nodules and papules. It primarily affects adults, particularly middle-aged women. The aetiology of chronic prurigo is unclear, but it can be associated with primary skin dermatoses and systemic conditions. Minimal data on chronic prurigo in children are available in the literature. While systemic therapies for chronic prurigo have significant side effects, targeted biologic and small-molecule inhibitors offer a promising treatment option with a good benefit–risk ratio. We report one of the first cases of an adolescent with chronic prurigo that was successfully controlled with dupilumab. Dupilumab treatment resulted in a fast, significant and sustainable improvement in the signs and symptoms of chronic prurigo, with favourable safety and tolerability profiles, highlighting its potential for recalcitrant cases and long-term remission.
UR - https://www.scopus.com/pages/publications/105046041706
U2 - 10.1093/skinhd/vzag050
DO - 10.1093/skinhd/vzag050
M3 - Article
AN - SCOPUS:105046041706
SN - 2690-442X
VL - 6
SP - 582
EP - 585
JO - Skin Health and Disease
JF - Skin Health and Disease
IS - 4
ER -